Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1987 1
1992 1
1994 1
1995 2
1996 1
1998 3
2000 2
2002 3
2005 2
2006 1
2007 4
2008 2
2009 5
2010 3
2012 2
2013 10
2014 4
2015 5
2016 8
2017 10
2018 9
2019 16
2020 16
2021 12
2022 13
2023 23
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

154 results

Results by year

Filters applied: . Clear all
Page 1
Testing for t(3;8) in MYC/BCL6 re-arranged large B cell lymphoma identifies a high risk subgroup with inferior survival.
Maybury BD, James LJ BSc (Hons), Phillips N, Venkatadasari I, Qureshi I, Riley JWE, Talbot G, Moosai S, Giles HV Dr, Chadderton N Mrs, Dowds J, Rakesh P, Crosland H, Haslam A, Lane S, Vega Gonzalez M, Davies D, Cherian G, Shenouda A, Kaudlay Sathyanarayana PK, Starczynski J, Rudzki Z, Chaganti S. Maybury BD, et al. Among authors: chaganti s. Blood. 2024 Apr 22:blood.2024024048. doi: 10.1182/blood.2024024048. Online ahead of print. Blood. 2024. PMID: 38648564
Ibrutinib as part of risk-stratified treatment for post-transplant lymphoproliferative disorder: The phase 2 TIDaL trial.
Chaganti S, Maycock S, McIlroy G, Jackson AE, Bishop R, Johnson S, Kanfer E, Kassam S, Cwynarski K, Wrench DJ, Arumainathan A, Fox CP, Johnson RJ, McKay P, Paneesha S, Rowntree C, Balotis C, Collins GP, Davies AJ, Wright J, Burns S Dr, Laurence ADJ, Wheatley K, Menne T. Chaganti S, et al. Blood. 2024 Apr 21:blood.2024023847. doi: 10.1182/blood.2024023847. Online ahead of print. Blood. 2024. PMID: 38643491
Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access scheme.
Oporto Espuelas M, Burridge S, Kirkwood AA, Bonney D, Watts K, Shenton G, Jalowiec KA, O'Reilly MA, Roddie C, Castleton A, Clesham K, Nicholson E, Alajangi R, Prabhu S, George L, Uttenthal B, Gabelli M, Neill L, Besley C, Chaganti S, Wynn RF, Bartram J, Chiesa R, Lucchini G, Pavasovic V, Rao A, Rao K, Silva J, Samarasinghe S, Vora A, Clark P, Cummins M, Marks DI, Amrolia P, Hough R, Ghorashian S. Oporto Espuelas M, et al. Among authors: chaganti s. Blood Cancer J. 2024 Apr 15;14(1):66. doi: 10.1038/s41408-024-01038-2. Blood Cancer J. 2024. PMID: 38622139 Free PMC article.
Outcome and feasibility of radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T in the UK.
Kuhnl A, Roddie C, Kirkwood AA, Chaganti S, Norman J, Lugthart S, Osborne W, Gibb A, Gonzalez Arias C, Latif A, Uttenthal B, Seymour F, Jones C, Springell D, Brady JL, Illidge T, Stevens A, Alexander E, Hawley L, O'Rourke N, Bedi C, Prestwich R, Frew J, Burns D, O'Reilly M, Sanderson R, Sivabalasingham S, Mikhaeel NG. Kuhnl A, et al. Among authors: chaganti s. Br J Haematol. 2024 Apr 9. doi: 10.1111/bjh.19453. Online ahead of print. Br J Haematol. 2024. PMID: 38594876
Outcomes after chimeric antigen receptor T-cell therapy across large B-cell lymphoma subtypes.
Bourlon C, Roddie C, Menne T, Norman J, O'Reilly M, Gibb A, Besley C, Chaganti S, Arias CG, Jones C, Dikair A, Allen S, Seymour F, Osborne W, Mathew A, Townsend W, Patten PE, Thoulouli E, Abdulgawad A, Lugthart S, Sanderson R, Kirkwood AA, Kuhnl A. Bourlon C, et al. Among authors: chaganti s. Haematologica. 2024 Apr 4. doi: 10.3324/haematol.2024.285010. Online ahead of print. Haematologica. 2024. PMID: 38572567 Free article.
Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial.
Mahadeo KM, Baiocchi R, Beitinjaneh A, Chaganti S, Choquet S, Dierickx D, Dinavahi R, Duan X, Gamelin L, Ghobadi A, Guzman-Becerra N, Joshi M, Mehta A, Navarro WH, Nikiforow S, O'Reilly RJ, Reshef R, Ruiz F, Spindler T, Prockop S. Mahadeo KM, et al. Among authors: chaganti s. Lancet Oncol. 2024 Mar;25(3):376-387. doi: 10.1016/S1470-2045(23)00649-6. Epub 2024 Jan 31. Lancet Oncol. 2024. PMID: 38309282
154 results